Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q2 2019 · 10-Q
Revenue$86.71M$86.71M+41.0% vs Q2 2018 Net Income-$1.27M-$1.27MN/M vs Q2 2018 EPS Diluted-$0.01-$0.01N/M vs Q2 2018 Gross Profit$65,607,000+57.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow$9,066,000N/M Free Cash Flowderived$6,669,000N/M Margins · derivedGross margin75.7%+7.9 pt vs Q2 2018
Operating margin1.4%+12.9 pt vs Q2 2018
Net margin-1.5%+23.7 pt vs Q2 2018
ended Jun 30, 2019 · filed Jul 25, 2019 · 25 d after period end